<DOC>
	<DOCNO>NCT02735850</DOCNO>
	<brief_summary>This phase II trial test combination SBRT L19-IL2 improve progression free survival patient limited metastatic non-small cell lung cancer ( NSCLC ) . Treatment divide two cohort : patient eligible ablative stereotactic body radiotherapy metastatic site ( treatment curative intent ) patient eligible stereotactic body radiotherapy site ( life prolongation ) .</brief_summary>
	<brief_title>Combination SABR L19-IL2 Patients With Stage IV Lung Cancer ( ImmunoSABR )</brief_title>
	<detailed_description>IMMUNOSABR include 138 patient . The trialpopulation divide two cohort : patient eligible ablative stereotactic body radiotherapy metastatic site ( treatment curative intent ) patient eligible stereotactic body radiotherapy site ( life prolongation ) .In single stage phase II trial aim demonstrate absolute increase progression free survival two year . . PFS determine time randomization disease progression , accord RECIST 1.1 , death due cause last patient contact alive progression-free . Patients randomize control ( L19-IL2 ) experimental arm ( L19-IL2 ) 1:1 ratio . The accrual period 29 month ( 2.41 year ) minimum follow-up 24 month ( 2 year ) , make total study duration 53 month ( 4.41 year ) . Comparison control experimental arm do use Log-Rank statistic . This test superiority one-sided desire type I error 0.10 power 0.80 . The randomization allocation 1:1 . Primary endpoint power calculation For ablative cohort : expect 2-year PFS 20 % control arm ( arm A ) 40 % experimental arm ( arm B ) . The study therefore power test difference PFS 2 year 20 % . The null hypothesis ( H0 ) difference PFS arm A arm B . This result sample size 72 patient evenly divide two arm 36 patient per arm . Considering dropout rate 10 % current experience , actual amount patient 40 per arm 80 total . For non-ablative cohort : expect 2-year PFS 10 % control arm ( arm C ) 30 % experimental arm ( arm D ) The study therefore power test difference PFS 2 year 20 % . The null hypothesis ( H0 ) difference PFS arm C arm D. This resuls sample size 52 patient evenly divide two arm 26 patient per arm . Considering dropout rate 10 % current experience , actual amount patient 29 per arm 58 total . The total number patient need trial sum amount patient ablative cohort ( 80 patient ) amount patient non-ablative cohort ( 58 patient ) : 138 patient . Secondary endpoint Simple univariate comparison outcome toxicity make treatment arm cohort use Chi-square test categorical data independent sample t-tests scale data . Secondary study parameter ( ) : Overall survival ( OS ) assess use survival table Kaplan-Meier curve . OS calculate day randomisation . Abscopal response , measure non-ablative cohort ( least one non-irradiated target lesion ) measure best response experimental standard treatment arm . Quality life ( EORTC QLQ-C30 version 3.0 QLQ-LC13 questionnaire ) record regular interval . Average change quality life report term absolute difference score , also term minimally clinically relevant change .</detailed_description>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Interleukin-2</mesh_term>
	<criteria>Histological confirm limited metastatic NSCLC patient . Two cohort patient allow : Synchronous oligometastatic eligible ablative stereotactic body radiotherapy sit . These patient maximum 3 metastatic lesion ( exclude brain ) eligible ablative treatment use SABR. , Other oligometastatic patient 10 metastatic lesion , eligible ablative stereotactic body radiotherapy , control disease ( i.e . progressive disease accord RECIST 1.1 ) follow primary chemotherapy platinum doublet , least one measurable lesion subject stereotactic body radiotherapy ( SABR ) , . Radiological image document lesion old 28 day study enrolment . Age 18 old . Prior treatment allow must discontinue least 4 week enrolment . All radiology study must perform within 28 day prior registration WHO performance status 02 ; Adequate bone marrow : Normal white blood cell count formula , normal platelet count , anemia require blood transfusion erythropoietin ; Adequate hepatic function : total bilirubin ≤ 1.5 x upper limit normal ( ULN ) institution ; ALT , AST , alkaline phosphatase ≤ 2.5 x ULN institution &lt; = 5 case liver metastasis ) ; Adequate renal function : creatinine clearance least 60 ml/min ; The patient capable comply study procedure ; Life expectancy least 12 week ; Men woman reproductive potential must willing practice acceptable method birth control study 12 week last dose study medication . Signed date write informed consent ; NSCLC activate ALK/EGFR ROS mutation . SABR require brain metastasis Previous chemotherapy platinum doublet . Patients progressive disease follow initial chemotherapy . Previous chemotherapy 25 week . Previous radiotherapy area would retreat SABR ; Other active malignancy malignancy within last 2 year ( exception localize skin basal/squamous cell carcinoma , bladder situ carcinoma ) ; History allergy intravenously administer proteins/peptides/antibodies ; HIV infection , active infection , active hepatitis ; Chronic systemic use corticosteroid use management cancer noncancerrelated illness ; Acute subacute coronary syndrome within last year , acute inflammatory heart disease , heart insufficiency irreversible cardiac arrhythmia ; Impaired cardiac function define leave ventricular ejection fraction ( LVEF ) &lt; 50 % ( study site 's low limit normal ) measure MUGA ECHO . ( LVEF measurement date back 8 week acceptable absence intercurrent use potentially cardiotoxic treatment cardiac medical history ) . Uncontrolled hypertensive disease History evidence active autoimmune disease ; Severe diabetic retinopathy ( neoangiogenesis target L19 outside tumor ) Major trauma , include surgery , within 4 week prior enter study ( neoangiogenesis target L19 outside tumor ) Any underlie medical psychiatric condition opinion investigator make administration study drug hazardous hinder interpretation study result ( e.g. , AE ) ; Unstable serious concurrent uncontrolled medical condition ; Pregnancy breastfeeding .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
</DOC>